Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Myasthenia Gravis × Hizentra × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1 Multiple Myeloma 1 Common Variable Immunodeficiency 1 Agammaglobulinemia 1

Interventions

rozanolixizumab 7 zilucoplan 6 efgartigimod alfa 5 telitacicept 4 ravulizumab 4 fludarabine 4 Cyclophosphamide 4 Prednisone 3 inebilizumab 2 Pyridostigmine Bromide 2 tofacitinib 1 thymoglobulin 1 remibrutinib 1 prednylidene 1 iptacopan 1 eculizumab 1 deltacortene 1 carmustine, poliferprosan 20 drug combination 1 blinatumomab 1 Walk Test 1 Tacrolimus 1 Sugammadex 1 Steroids 1 Robotic Surgical Procedures 1 Rituximab 1 Psychodrama 1 Prednisolone 1 Peripheral Blood Stem Cell Transplantation 1 Oxaloacetic Acid 1 Neostigmine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04728425 2025-04-27

MG_SCIG

University Health Network, Toronto

Phase 2 Completed

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡